Thrombolytic Science, LLC (TSI) has been granted a second patent by the USPTO. The patent was granted for a novel treatment applicable to ischemic stroke, one of the leading causes of morbidity and mortality.
Thrombolytic Science, LLC (TSI) announced progress with 10 patients enrolled in its prospective, randomized, multicenter Phase 2 clinical trial, designed to confirm the safety and ...